8YY — Biolidics Cashflow Statement
0.000.00%
Last trade - 00:00- SG$8.94m
- SG$10.78m
- SG$1.32m
Annual cashflow statement for Biolidics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.81 | -4.68 | -6.04 | -9.85 | -2.49 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.072 | 2.2 | 0.697 | 5.53 | 0.315 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.46 | -0.939 | -0.531 | 0.07 | -0.034 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.56 | -2.43 | -4.62 | -3.06 | -1.97 |
| Capital Expenditures | -0.686 | -0.449 | -0.562 | -0.093 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.015 | -0.09 | -0.299 | 0.098 | -2.69 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.671 | -0.539 | -0.861 | 0.005 | -2.69 |
| Financing Cash Flow Items | 0 | -0.028 | 0 | -0.223 | -0.058 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.258 | 7.5 | -1.16 | 4.18 | -0.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.47 | 4.64 | -6.71 | 1.07 | -4.85 |